FDA refuses to file NDA for ezetimibe/atorvastatin

Merck & Co. Inc. (NYSE:MRK) disclosed in an SEC filing that FDA refused to file an NDA for ezetimibe/atorvastatin ( MK-0653C) to treat dyslipidemia. The company said the agency indicated that addition...